MTOR and breast carcinoma: The hypothesis of synergism between mTOR inhibitors and taxanes was also under investigation in a phase III study, where 403 patients with HER2- breast cancer showing no response after four cycles of neoadjuvant epirubicin and cyclophosphamide (with or without bevacizumab) were randomised to receive either paclitaxel alone, or paclitaxel plus everolimus.